Specialty Drugs Offer “Reasonable” Value, Tufts Analysis Finds
This article was originally published in The Pink Sheet Daily
The study is the first to systematically evaluate the additional health gains and costs associated with specialty drugs, the researchers note.
You may also be interested in...
US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost
HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.
Public confidence in the Johnson & Johnson vaccine may be shaken. But faith in the regulatory system is solid, according to a recent poll, an Administration official maintained.
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.